By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sankyo Pharma Inc. 

Two Hilton Court

Parsippany  New Jersey  07054  U.S.A.
Phone: 973-359-2600 Fax: 973-359-2645





Forest  Developer and Forest's partner in the promotion of Benicar, an angiotensin II receptor blocker (ARB) for the treatment of hypertension.

Company News
Sankyo Pharma Inc. Release: U.S. Subsidiaries Join Together To Form Daiichi Sankyo, Inc. 4/3/2006 11:03:22 AM
Sankyo Pharma Inc. Release: First Data To Show Addition Of A Bile Acid Sequestrant (WelChol, colesevelam HCl) To Statin Therapy Significantly Reduces Median Hs-CRP Levels 11/15/2005 11:30:36 AM
Sankyo Pharma Inc. Halts Development Of Pactimibe (CS-505) 10/26/2005 12:06:24 PM
Sankyo Pharma Inc. Release: New Study Finds Additional LDL-C Drops When WelChol(R) (colesevelam HCl) Is Added To Fenofibrate In Patients With Mixed Hyperlipidemia10/19/2005 5:13:18 PM
Daiichi Pharmaceutical (JPN), Sankyo Company, Ltd. (SKXOF.PK) Sign Basic Agreement To Integrate Businesses10/19/2005 5:12:51 PM
Sankyo Pharma Inc. Release: New Study Demonstrates Co-Administration Of WelChol(R) (colesevelam HCI) And TriCor(R) (fenofibrate tablets) Resulted In No Significant Drug-Drug Interactions10/19/2005 5:11:50 PM
Kirin Brewery Co., Ltd. (KNBWY) , Sankyo Company, Ltd. (SKXOF.PK) To Terminate Joint Marketing Of Renal Anemia Drug ESPO And Leukopenia Drug GRAN By Next March10/19/2005 5:11:50 PM
Sankyo Pharma Inc. Release: New Data Demonstrates That BENICAR And BENICAR HCT Achieve JNC 7 Blood Pressure Goals10/19/2005 5:11:31 PM
Dendrite International, Inc. (DRTE) Awarded Sales And Marketing Data Outsourcing Contract From Sankyo Pharma Inc.10/19/2005 5:10:52 PM
Forest Laboratories, Inc. (FRX) Announces That Neramexane Did Not Demonstrate Statistical Significance In Recently Completed Phase III Trial In Patients With Moderate To Severe Alzheimer's Disease10/19/2005 5:10:29 PM